`
`
`
`10 ' e11;carn1e11
`
`
`F1'°m= —
`Sent:
`Fri Oct 10 2003 12:48:19 EDT
`
`
`To:
`
`
`
`Subject:
`
`
`
`
`Pu.n1aPl1a1111 Update
`
`
`
`
`Hi Everyone,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`As you know, we have brought a new product in to o11r pipeline. The product, BGOOOI 2, will be
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`developed i11 Psoriasis and MS. Fu1naPharni will participate on a Management Team with routine
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`review and buy-in of plans, but the studies will be conducted entirely by Biogen. Rather than wait until
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`the next milestone meeting, I am sending this e-mail to give you a very draft overview of the prograin
`
`
`
`
`
`
`
`because we will need resources assigned iininediately.
`
`
`
`
`
`
`Currelitly,
`Medical Director
`
`
`Analyst for MS,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`is the Acting Medical Director for Psoriasis, Gilmore O'Neill is the
`is the Business Analyst for Psoriasis: is the Business
`
`
`
`
`
`
`
`
`
`
`
`
`
`t e MCD for both MS and Psoriasis.
`
`
`
`Page 1 0”
`
`Biogen Exhibit 2318
`Coalition V. Biogen
`IPR2015-01993
`
`
`
`http:.r’.r'i'el-web.r'RelatiVity.Distributed.=’Download. aspx?A1‘tifa ctID=l 1643 60&GUlD=0c4 l 4. ..
`
`l 1;’ 1 252015
`
`
`
`Page 1 of 2
`
`Biogen Exhibit 2318
`Coalition v. Biogen
`IPR2015-01993
`
`
`
`
`
`Page 2 of2
`
`
`
`
`
`
`
`
`
`
`
`
`Please Contact me if you have any questions 01' concerns.
`
`
`
`
`
`Page 2 of 2
`
`
`
`htlp:.ff1'el-\veb;’Relativity.Dist1‘ibuted.="Download.aspx?A1'tifactID=1 1643 60&GUID=0c414...
`
`
`1 1;’ 1252015
`
`Page 2 of 2